These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23673909)

  • 1. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.
    Yahalom G; Tsabari R; Molshatzki N; Ephraty L; Cohen H; Hassin-Baer S
    Clin Neuropharmacol; 2013; 36(3):78-83. PubMed ID: 23673909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with Lately Diagnosed Cerebrotendinous Xanthomatosis.
    Yunisova G; Tufekcioglu Z; Dogu O; Bilgic B; Kaleagasi H; Akca Kalem S; Lohmann E; Gurvit HI; Emre M; Hanagasi HA
    Neurodegener Dis; 2019; 19(5-6):218-224. PubMed ID: 32349000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
    Keren Z; Falik-Zaccai TC
    Pediatr Endocrinol Rev; 2009 Sep; 7(1):6-11. PubMed ID: 19696711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The wide spectrum of cerebrotendinous xanthomatosis: Case report of a rare but treatable disease.
    Rosafio F; Cavallieri F; Guaraldi P; Taroni F; Nichelli PF; Mandrioli J
    Clin Neurol Neurosurg; 2016 Apr; 143():1-3. PubMed ID: 26874936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malar rash and hand tremor in early symptoms of cerebrotendinous xanthomatosis and the effect of chenodeoxycholic acid on them.
    Yılmaz BK; Çelik H
    J Clin Lipidol; 2024; 18(3):e452-e464. PubMed ID: 38461119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.
    Catarino CB; Vollmar C; Küpper C; Seelos K; Gallenmüller C; Bartkiewicz J; Biskup S; Hörtnagel K; Klopstock T
    J Neurol; 2018 Feb; 265(2):388-393. PubMed ID: 29260356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
    Weissfeld T; Ratliff J
    J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
    Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
    Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
    Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
    Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cerebrotendinous xanthomatosis in pregnancy: Patient and physician perspectives.
    Duell PB; Dutta R; Wolf A; Rosengrant H
    J Clin Lipidol; 2023; 17(5):700-703. PubMed ID: 37543441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.
    Amador MDM; Masingue M; Debs R; Lamari F; Perlbarg V; Roze E; Degos B; Mochel F
    J Inherit Metab Dis; 2018 Sep; 41(5):799-807. PubMed ID: 29560583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment.
    Martini G; Mignarri A; Ruvio M; Valenti R; Franci B; Del Puppo M; Federico A; Nuti R; Dotti MT
    Calcif Tissue Int; 2013 Mar; 92(3):282-6. PubMed ID: 23212544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report.
    Koyama S; Okabe Y; Suzuki Y; Igari R; Sato H; Iseki C; Tanji K; Suzuki K; Ohta Y
    BMC Neurol; 2022 May; 22(1):193. PubMed ID: 35614401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene.
    Suh S; Kim HK; Park HD; Ki CS; Kim MY; Jin SM; Kim SW; Hur KY; Kim KW; Kim JH
    Eur J Med Genet; 2012 Jan; 55(1):71-4. PubMed ID: 21958693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
    Heller R; Grau AJ; Schäbitz WR; Schwaninger M
    Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
    Verrips A; Wevers RA; Van Engelen BG; Keyser A; Wolthers BG; Barkhof F; Stalenhoef A; De Graaf R; Janssen-Zijlstra F; Van Spreeken A; Gabreëls FJ
    Metabolism; 1999 Feb; 48(2):233-8. PubMed ID: 10024088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey.
    Zubarioglu T; Kiykim E; Yesil G; Demircioglu D; Cansever MS; Yalcinkaya C; Aktuglu-Zeybek C
    Acta Neurol Belg; 2019 Sep; 119(3):343-350. PubMed ID: 29058268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chenodeoxycholic acid (CDCA) treatment during pregnancy in women with cerebrotendinous xanthomatosis (CTX): Lessons learned from 19 pregnancies.
    Zaccai TCF; Hassin-Baer S; Kfir NC; Duell PB; Neerhof M; Sloma R; Roitman M; Kisanuki YY; Verrips A; DeBarber AE
    Genet Med; 2024 May; 26(5):101086. PubMed ID: 38288684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.
    Wong JC; Walsh K; Hayden D; Eichler FS
    J Inherit Metab Dis; 2018 Jul; 41(4):647-656. PubMed ID: 29484516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.
    Berginer VM; Gross B; Morad K; Kfir N; Morkos S; Aaref S; Falik-Zaccai TC
    Pediatrics; 2009 Jan; 123(1):143-7. PubMed ID: 19117873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.